On Air Now

Current Show

Coast to Coast AM   12:00 AM - 5:00 AM

Call Coast to Coast now at 1-800-825-5033

Show Info »

Upcoming Shows

Program Schedule »

Listen

Listen Live Now » 590 AM Kalamazoo, MI

Weather

Current Conditions(Kalamazoo,MI 49001)

More Weather »
46° Feels Like: 41°
Wind: NW 10 mph Past 24 hrs - Precip: 0”
Current Radar for Zip

Tonight

Mostly Clear 41°

Tomorrow

Sunny 65°

Tues Night

Clear 46°

Alerts

FDA approves Theravance's lung drug for wider use

A view shows the U.S. Food and Drug Administration (FDA) logo at the lobby of its headquarters in Silver Spring, Maryland August 14, 2012. R
A view shows the U.S. Food and Drug Administration (FDA) logo at the lobby of its headquarters in Silver Spring, Maryland August 14, 2012. R

(Reuters) - The U.S. Food and Drug Administration approved Theravance Inc's antibiotic lung drug to treat a type of bacterial pneumonia affecting hospitalized patients, particularly those on ventilators.

The drug, Vibativ, will reach the market in the third quarter of 2013 for its expanded use. The drug is already approved in the United States and Canada to treat bacterial skin infections.

The disease, also known as nosocomial pneumonia, is a serious lung infection as patients, particularly those on ventilators, often cannot fight the infection.

The regulator said on Friday that Vibativ will be prescribed only when alternative treatments are not suitable and the expanded use is to treat only bacterial pneumonia due to staphylococcus aureus. (http://link.reuters.com/hez98t)

Vibativ is already approved in Europe for the treatment of adults with nosocomial pneumonia.

Theravance's shares were up about 2 percent at $38.25 in after-market trading.

The shares closed up 10 percent at $37.5 on the Nasdaq following a Daily Mail's market report that GlaxoSmithKline is lining up a $55 per share bid for Theravance.

Comments